메뉴 건너뛰기




Volumn 7, Issue 11, 2000, Pages 1145-1161

COX-2 selectivity and inflammatory processes

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

EID: 0033761157     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/0929867003374255     Document Type: Review
Times cited : (124)

References (131)
  • 1
    • 0007355057 scopus 로고    scopus 로고
    • Inducible Enzymes in the Inflammatory Response; D.A. Willoughby and Tomlinson Eds; Birkhaeuser Verlag Basel
    • (1999) , pp. 1-30
    • Pairet, M.1    Van Ryn, J.2    Distel, M.3
  • 9
    • 0007402137 scopus 로고    scopus 로고
    • Selective COX-2 Inhibitors. Pharmacology, Clinical Effects and Therapeutic Potential. J. Vane and J. Botting Eds; Kluwer Academic Publishers: Dordrecht
    • (1998) , pp. 19-26
    • Browner, M.F.1
  • 15
    • 85037806400 scopus 로고    scopus 로고
    • Merck and Co Inc., Patent application GB 2319 032 A date of publication 13.05.1998
  • 28
    • 85037803452 scopus 로고    scopus 로고
    • Kabushiki Kaisha Yakkult Honsha, Tokyo, Patent application WO 97/09977, date of filing 11.9.1996
  • 129
    • 0007399448 scopus 로고    scopus 로고
    • Food and Drug Administration Center for Drug Evaluation and Research. Athritis Advisory Committee, Open Public Hearing. Tuesday, December 1, 1998
    • (1998)
  • 131
    • 85037804811 scopus 로고    scopus 로고
    • United States of America Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Arthritis Advisory Committee. Review of NDA 21-042, Vioxx TM (Rofecoxib), Merck Research Laboratories. Tuesday April 20, 1999
    • (1999)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.